nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-00F709B6·Framework v5.0·Pipeline v0.4·Evaluated 15 Jun 2026·OECD: 3.1 Basic medicine·Subfield: Genetics·Basis: Full text·Type: Systematic review or meta-analysis

Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.

Mohseni et al.Mohseni, Tavakoli, Ghazipoor et al.·2025·Frontiers in nutrition·10.3389/fnut.2025.1494351 ↗

In brief

A clinically useful synthesis showing curcumin benefits ulcerative colitis but not Crohn's disease, constrained by unexplored extreme heterogeneity and missing certainty-of-evidence assessment.

ReliabilityCaveats3 of 4 checks completeRead the 2 entries ↓
Abstract

INTRODUCTION: Inflammatory Bowel Disease (IBD), encompassing Crohn disease (CD) and ulcerative colitis (UC), presents complex challenges in management due to dysregulated immune responses and genetic predispositions. This study explored the potential of curcumin as an adjunctive therapy in IBD, assessing its efficacy and safety through a systematic review of clinical trials to enhance treatment strategies and outcomes.

METHODS: To identify placebo-controlled randomized clinical trials on curcumin treatment in IBD, databases such as Medline/PubMed, Scopus, Embase, Web of Knowledge, and Google Scholar were searched till May 2024. Inclusion criteria focused on RCTs comparing curcumin with placebo in IBD patients, with data extraction and analysis conducted using established methodologies and tools for comprehensive synthesis and assessment of study findings.

RESULTS: In this meta-analysis, 13 placebo-controlled RCTs on curcumin treatment in IBD were included after screening 362 records and conducting a full-text review. Most trials focused on UC patients and were published post-2010, utilizing oral curcumin with varying dosages and durations. The analysis showed curcumin's significant efficacy in achieving clinical remission and response in UC patients, with heterogeneity observed. Adverse events and withdrawal rates did not significantly differ between curcumin and placebo groups. In CD patients, curcumin did not show superiority over placebo for clinical and endoscopic remission.

CONCLUSION: The findings highlight curcumin's potential as a treatment for UC but indicate inconclusive results for CD, emphasizing the need for further research. The multifaceted mechanisms of curcumin's efficacy in IBD involve anti-inflammatory, antioxidant, microbiota modulatory, and immune-regulating properties. Further research is warranted to enhance understanding and treatment efficacy.

SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024567247.

Strengths · Limitations

Strengths

#contribution

Clinically useful UC versus CD differentiation

The review separates ulcerative colitis from Crohn's disease rather than pooling them, reporting a positive UC signal and a null CD result. This is clinically meaningful given the distinct pathophysiology of the two conditions and is reported without spin.

↳ Results, UC and CD efficacy subsections; Conclusion

#methodological rigour

Sound systematic-review process and reporting

Five databases plus Google Scholar were searched with snowball screening, four independent researchers screened and extracted with consensus resolution, and pooled risk ratios with 95% confidence intervals and heterogeneity statistics are reported throughout.

↳ Methods, Study selection and Data extraction; Results, Figures 3-4

#reporting

Appropriately hedged, well-structured presentation

The paper follows a logical structure and uses cautious language ('might be more beneficial', 'further research is warranted'), presenting both positive and null findings without overstatement.

↳ Abstract; Conclusion

Limitations

#methodological rigour

Extreme heterogeneity left unexplored

Clinical remission in UC carries I²=88% heterogeneity, yet no subgroup or sensitivity analysis examines obvious sources such as formulation, dose (0.1-10 g), or disease severity. This weakens interpretability of the pooled estimate.

↳ Methods, Statistical analysis; Results, UC efficacy subsection

#positioning

No publication bias or certainty assessment

No funnel plot, Egger's test, or other publication bias assessment is reported, and no GRADE certainty-of-evidence rating is provided, both standard expectations for a contemporary clinical systematic review. Readers cannot judge whether the positive UC findings are robust to small-study effects.

↳ Methods and Results (assessment absent)

#methodological rigour

Selective emphasis across ITT and PP

Endoscopic remission is significant in per-protocol analysis (RR 2.11, p=0.007) but not in intention-to-treat (RR 3.81, p=0.06), and the framing leads with the significant analysis without flagging the discordance as a limitation.

↳ Results, Clinical efficacy of curcumin versus placebo in UC

Does this match your read? Add your assessment ↓

Nabu Commentary

This is a competently executed but methodologically incomplete systematic review whose core finding—curcumin benefits ulcerative colitis but not Crohn's disease—is clinically meaningful and appropriately hedged. The Methodological Rigour and Positioning scores are constrained by three converging gaps: the very high heterogeneity (I²=88%) in the primary UC outcome is acknowledged but never analytically explored, no publication bias assessment is reported, and no GRADE certainty rating is provided. Reporting scored slightly higher on the strength of clear structure and accurate hedging, though tangential discussion content on mechanisms and rheumatoid arthritis dilutes the argument. Impact potential is moderate and converges on agenda-setting for future UC trials rather than immediate practice change, with the unresolved heterogeneity and lack of standardized dosing as the binding constraints. The Crohn's analysis (two trials, N=92) is too small to support conclusions and is correctly framed as inconclusive.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.0±0.2

Contribution
3.2

The review delivers an updated synthesis of 13 placebo-controlled RCTs through May 2024 and usefully separates UC (positive signal) from CD (null), but the advance is incremental and the introduction does not articulate what gap it fills relative to prior curcumin-IBD syntheses. The 2.5-3.4 band fits a real but limited contribution.

Introduction final paragraph; Results, Description of included studies and UC/CD efficacy subsections

curcumin might be more beneficial in addressing UC in contrast to CD

Methodological Rigour
2.8

The process is methodologically sound (multi-database search, four independent screeners with consensus, random-effects modeling, RoB assessment, ITT and PP analyses), but material gaps cap the score: no publication bias assessment, no GRADE certainty rating, and no subgroup/sensitivity analysis to explore I²=88% heterogeneity across widely varying formulations and doses. These place execution in the 2.5-3.4 band.

Methods, Statistical analysis and Data extraction; Results, UC efficacy subsection

Due to high heterogeneity, random-effects models were used to calculate the summary effect size.

Reporting
3.4

The paper is clearly structured with effect sizes and confidence intervals reported throughout and appropriately hedged conclusions, but precision is uneven where abstract framing compresses the I²=88% caveat and discussion drifts into tangential mechanism and rheumatoid-arthritis material. This supports a score in the upper-middle range.

Abstract Conclusion; Results UC efficacy subsections; Discussion middle paragraphs

curcumin's significant efficacy in achieving clinical remission and response in UC patients, with heterogeneity observed

Positioning
2.9

The review situates curcumin within IBD mechanisms and the treatment landscape and includes a limitations section, but it does not engage prior systematic reviews on the same topic, lacks a GRADE certainty framework, and lists limitations without quantifying their effect on interpretation. This fits the 2.5-3.4 band.

Introduction; Discussion limitations paragraph; Conclusion

a notable proportion of low-quality pooled studies, research conducted in settings of varying quality

Reliability

Caveats3 of 4 checks


Internal CoherenceNoted

Core numerical reporting is internally consistent (13 RCTs, record counts, effect estimates with CIs), but interpretive framing in the Abstract and Discussion emphasizes significant outcomes while non-significant ITT/PP results for the same endpoints receive less prominence, and very high heterogeneity is reported without analytical exploration.

Research ConductNoted

Preregistration on PROSPERO and an appropriate ethics statement for a review of published data are declared, but no conflict-of-interest declaration is visible, the data availability statement is generic with no repository, and protocol timing relative to search/screening cannot be confirmed from the text.

Flags: 3 declared / 5 total

Reference IntegrityPending

Not yet checked.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceSynthesis
Route to useNamed
AdvanceConsolidates
BeneficiariesSmall
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The meta-analysis pools 13 independent placebo-controlled RCTs across multiple countries and sites, providing external validation of curcumin's clinical remission and response effects in UC patients.

From the paper
“The findings of this review may inform clinical practice, guide future research directions, and contribute to optimizing treatment strategies for individuals living with IBD.”

The paper names clinicians managing IBD patients as those who would apply curcumin as adjunctive therapy in clinical practice, though without specifying the exact decision setting.

Pathway

Gastroenterologists and IBD care teams could adopt standardized oral curcumin as an adjunctive therapy for ulcerative colitis patients to improve remission rates.

Barrier

High heterogeneity across trials, variable dosages and formulations, and inconclusive evidence in Crohn's disease limit confidence in clinical adoption.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis

    Milad Sabzevary-Ghahfarokhi, Mojtaba Shohan, Hedayatollah Shirzad, et al. · 2018 · Basic medicine

    Primary claim

    Oxidative stress in inflamed colonic tissue can induce Nrf2 gene expression. The performance of Nrf2 transcription factor may lead to the induction of GST-A4 and PRDX1.

    Unsupported
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. Curcumin for maintenance of remission in ulcerative colitis

    Kumar, Ahuja, Sankar, et al. · 2012 · Clinical medicine

    Evidence Score
    3.8±0.1
    Reliability
    Caveats
  3. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials

    Coelho, Romi, Ferreira, et al. · 2020 · Clinical medicine

    Evidence Score
    3.1±0.1
    Reliability
    Caveats

How the rubric works →